Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin
详细信息 查看全文
- 作者：Sher ; Lawrence D. ; Poole ; Michael D. ; Von Seggern ; Kristen ; Wikler ; Matthew A. ; Nicholson ; Susan C. ; et. al.
- 刊名：Otolaryngology - Head and Neck Surgery
- 出版年：2002
- 出版时间：September, 2002
- 年：2002
- 卷：127
- 期：3
- 页码：182-189
- 全文大小：88.8 K
文摘
Objective: We sought to evaluate gatifloxacin in adults with acute uncomplicated bacterial rhinosinusitis. Study Design: TeqCES was an open-label, multicenter, noncomparative study of the safety and efficacy of gatifloxacin. More than 11,000 adult patients with acute uncomplicated rhinosinusitis received gatifloxacin 400 mg once daily for 10 days. Results:Moraxella catarrhalis (91 % β-lactamase producers), Haemophilus influenzae (28 % β-lactamase producers), Streptococcus pneumoniae (18 % intermediately resistant and 14 % fully resistant to penicillin), and Staphylococcus aureus were the predominant pathogens isolated from purulent nasal discharge. More than 99 % of rhinosinusitis pathogens isolated from the nasopharynx of patients meeting the clinical criteria for rhinosinusitis were susceptible to gatifloxacin. Among 10,353 patients whose clinical response could be determined, 91.6 % were cured. Clinical cure rates exceeded 90 % for the major pathogens. Gatifloxacin was well tolerated; drug-related adverse events that occurred in 1 % or more of patients were nausea (4.4 % ), dizziness (1.8 % ), diarrhea (1.4 % ), and headache (1.0 % ). Conclusion: Gatifloxacin is effective for patients with acute bacterial rhinosinusitis in the community. (Otolaryngol Head Neck Surg 2002;127:182-89.)